Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.86 per share for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2019-11-14
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $1.90, a 16.30% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $2.27.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $0.87, a 40.41% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-03-31 was $1.46.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed |
|---|---|---|---|---|
| 2019-09-30 | $1.86 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $1.88 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $1.90 10-Q · filed 2019-05-15 | |||
| 2018-09-30 | $2.36 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $2.23 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $2.27 10-Q · filed 2019-05-15 | |||
| 2013-09-30 | $4.41 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $0.98 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $0.87 10-Q · filed 2013-05-09 | |||
| 2012-09-30 | $6.66 10-Q · filed 2013-11-12 | $1.48 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | $1.48 10-Q · filed 2013-08-08 | |||
| 2012-03-31 | $1.46 10-Q · filed 2013-05-09 | |||
| 2011-09-30 | $2.62 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | $3.14 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |